afundas-l

afundas-l Uses, Dosage, Side Effects, Food Interaction and all others data.

afundas-l (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. It is typically administered intravenously. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall.

afundas-l is an antifungal drug, and belongs to a new class termed the echinocandins. It is used to treat Aspergillus and Candida infection, and works by inhibiting cell wall synthesis. Antifungals in the echinocandin class inhibit the synthesis of glucan in the cell wall, probably via the enzyme 1,3-beta glucan synthase. There is a potential for resistance development to occur, however in vitro resistance development to afundas-l by Aspergillus species has not been studied.

afundas-l
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	afundas-l
Availability	Prescription only
Generic	Caspofungin
Caspofungin Other Names	Caspofungin, Caspofungina
Related Drugs	ciprofloxacin, fluconazole, Augmentin, amoxicillin / clavulanate, vancomycin, gentamicin, Diflucan, itraconazole, amphotericin b, voriconazole
Weight	50mg, 70mg
Type	Powder, For Solution
Formula	C₅₂H₈₈N₁₀O₁₅
Weight	Average: 1093.331 Monoisotopic: 1092.643062174
Protein binding	97%
Groups	Approved
Therapeutic Class
Manufacturer	Mn Pharmaceuticals
Available Country	Saudi Arabia
Last Updated:	September 19, 2023 at 7:00 am

Uses

afundas-l is an echinocandin used to treat a variety of fungal infections.

For the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies.

afundas-l is also used to associated treatment for these conditions: Abscess, Intra-Abdominal, Candidemia, Esophageal Candidiasis, Infections, Fungal, Oropharyngeal Candidiasis, Peritonitis, Invasive, refractory Aspergillosis, Pleural space infections

How afundas-l works

afundas-l inhibits the synthesis of beta-(1,3)-D-glucan, an essential component of the cell wall of Aspergillus species and Candida species. beta-(1,3)-D-glucan is not present in mammalian cells. The primary target is beta-(1,3)-glucan synthase.

Toxicity

Side effects include rash, swelling, and nausea (rare)

Food Interaction

No interactions found.

afundas-l Disease Interaction

Moderate: liver disease, hepatotoxicity

Elimination Route

92% tissue distribution within 36-48 hours after intravenous infusion

Half Life

9-11 hours

Clearance

12 mL/min [After single IV administration]

Elimination Route

After single intravenous administration of [3H] caspofungin acetate, excretion of caspofungin and its metabolites in humans was 35% of dose in feces and 41% of dose in urine.